U.S., Feb. 15 -- ClinicalTrials.gov registry received information related to the study (NCT06828588) titled 'Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment with HER2-targeted Therapy' on Jan. 29.
Brief Summary: The purpose of this study is to determine if the radiotracer, [68Ga]Ga-ABY-025, used for PET imaging can help us better identify and visualize lesions or tumors, in patients who are receiving standard of care therapy HER2+ cancers.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Locally Advanced Cancer
Metastatic Cancer
Intervention:
DRUG: ABY-025 Loading Dose
Subjects will receive a loading dose (400 micrograms) of ABY-025 prior to the [68Ga]Ga-ABY-025 infusion.
DRUG: [68Ga]Ga-AB...